We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies

Drs3.1

Drostanolone (Masteron) Research

Mostly mechanism / observational

6 peer-reviewed studies

What the evidence says

Mostly mechanism / observational

Most Drostanolone (Masteron) studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.

Most evidence is from medium-quality randomised trials published 1975–1995.

Based on 6 studies · 2 RCTs

Confidence

Low confidence

By outcome

Men's vitality
Mostly mechanism / observational4 studies
Breast cancer (historical/obsolete)
Mostly mechanism / observational3 studies
Lean mass & physique (claimed, unproven)A DHT-derived anabolic-androgenic steroid used illicitly for "hardening"; no human physique trials exist, and it adversely affects lipids and the HPTA. A controlled substance. · Not established (no human trials)
Too few graded studies1 study

Older research base

Newest study from 1995

197519851995

1RCT1975

Bennett MB, Helman P, Palmer P · S Afr Med J (1975)

2RCT1976

Chowdhury MS, Banks AJ, Bond WH, Jones WG, Ward HW · Clin Oncol (1976)

3In Vitro1983

In plain English: These data demonstrate significant additive growth-inhibitory activity of 5-FU and MDTP in combination against MCF-7 in vitro, thus affirming their antitumor effects in vivo.

Fujita H, Teller MN, Green S, Kreis W. · Eur J Cancer Clin Oncol (1983)

Mechanistic/outcome anchor for the anti-estrogenic anti-tumour signal: 2α-methyl-DHT propionate (drostanolone propionate, 'MDTP') inhibited growth of human MCF-7 breast-carcinoma cells in vitro
MDTP produced 16-94% growth inhibition over its tested dose range and was additive/synergistic with 5-fluorouracil
Demonstrates a direct anti-proliferative effect on a human estrogen-responsive breast-cancer line, consistent with its non-aromatizable, anti-estrogenic DHT pharmacology

View source

4Animal1982

In plain English: Administration of MDTP at 1.25 to 5 mg/kg/day yielded 15 to 48% tumor CR [complete remission]... Therapy with the cytotoxic drug 5-FUra in combination with the androgen analog MDTP is highly efficacious against induced mammary carcinomas.

Teller MN, Stock CC, Bowie M, Chou TC, Budinger JM. · Cancer Res (1982)

Foundational animal-efficacy study: drostanolone propionate ('MDTP') induced 15-48% complete remissions of carcinogen-induced rat mammary carcinomas as a single agent
Combined with 5-fluorouracil it produced 75-96% complete remissions with marked synergism, controlling new-tumour appearance
Establishes the in-vivo anti-mammary-tumour activity of the DHT-class androgen that underpinned its clinical breast-cancer use

5In Vitro1992

In plain English: The major metabolites of mesterolone and drostanolone were identified as 1 alpha-methyl-androsterone and 2 alpha-methyl-androsterone, respectively.

de Boer D, de Jong EG, Maes RA, van Rossum JM. · J Steroid Biochem Mol Biol (1992)

Foundational pharmacology/identity anchor: characterizes drostanolone as 2α-methyl-17β-hydroxy-5α-androstan-3-one — a methyl-DHT, confirming the non-aromatizable DHT-derivative chemistry
Defines its urinary metabolites (chiefly 2α-methyl-androsterone) for anti-doping detection
The compound was characterized specifically to add it to doping-control procedures — underscoring that it is a doping agent, not a therapeutic

View source

6Observational1995

In plain English: From 1990 on, a wide range of mostly injectable steroids including nandrolone, metenolone, drostanolone and testosterone were administered. Polydrug abuse including several anabolics in combination with stimulants and diuretics was also widespread.

Delbeke FT, Desmet N, Debackere M. · Int J Sports Med (1995)

Mandatory counter-evidence on the modern use: doping-control surveillance of competing bodybuilders found drostanolone among the injectable steroids abused — documenting the off-label physique use WITHOUT any evidence of benefit
Up to 38-58% of controlled athletes in some federations tested positive; polydrug abuse (anabolics + stimulants + diuretics) was widespread
Confirms that drostanolone's contemporary life is illicit doping, not a trialled physique intervention — there are no human performance or body-composition trials to cite

View source

View in Research Library

Drostanolone (Masteron) Research

Mostly mechanism / observational

Hormonal therapy of breast cancer with special reference to Masteril therapy.

A comparison of drostanolone propionate (Masteril) and nandrolone decanoate (Deca-durabolin) in the treatment of breast carcinoma.

Effects of 5-fluorouracil and 2 alpha-methyldihydrotestosterone propionate on the growth of human breast carcinoma MCF-7 in vitro.

Therapy of 7,12-dimethylbenz(a)anthracene-induced rat mammary carcinomas with combinations of 5-fluorouracil and 2 alpha-methyldihydrotestosterone propionate.

The methyl-5 alpha-dihydrotestosterones mesterolone and drostanolone; gas chromatographic/mass spectrometric characterization of the urinary metabolites.

The abuse of doping agents in competing body builders in Flanders (1988-1993).